Cardiff Oncology Future Growth
Future criteria checks 0/6
Cardiff Oncology's revenue and earnings are forecast to decline at 34.8% and 27.9% per annum respectively while EPS is expected to decline by 18.3% per annum.
Key information
-27.9%
Earnings growth rate
-18.3%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | -34.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -71 | -62 | -67 | 4 |
| 12/31/2025 | 0 | -55 | -49 | -48 | 5 |
| 12/31/2024 | 1 | -46 | -43 | -38 | 5 |
| 9/30/2024 | 1 | -43 | -35 | -35 | N/A |
| 6/30/2024 | 1 | -41 | -32 | -32 | N/A |
| 3/31/2024 | 1 | -40 | -31 | -30 | N/A |
| 12/31/2023 | 0 | -41 | -31 | -31 | N/A |
| 9/30/2023 | 0 | -41 | -34 | -33 | N/A |
| 6/30/2023 | 0 | -40 | -33 | -33 | N/A |
| 3/31/2023 | 0 | -39 | -33 | -32 | N/A |
| 12/31/2022 | 0 | -39 | -35 | -34 | N/A |
| 9/30/2022 | 0 | -39 | -33 | -32 | N/A |
| 6/30/2022 | 0 | -38 | -30 | -30 | N/A |
| 3/31/2022 | 0 | -34 | -28 | -27 | N/A |
| 12/31/2021 | 0 | -28 | -23 | -23 | N/A |
| 9/30/2021 | 0 | -25 | -21 | -21 | N/A |
| 6/30/2021 | 0 | -23 | -19 | -19 | N/A |
| 3/31/2021 | 0 | -24 | -19 | -19 | N/A |
| 12/31/2020 | 0 | -23 | -17 | -16 | N/A |
| 9/30/2020 | 0 | -20 | -15 | -14 | N/A |
| 6/30/2020 | 0 | -20 | -14 | -14 | N/A |
| 3/31/2020 | 0 | -17 | -13 | -13 | N/A |
| 12/31/2019 | 0 | -17 | -13 | -13 | N/A |
| 9/30/2019 | 0 | -17 | -14 | -14 | N/A |
| 6/30/2019 | 0 | -16 | -14 | -14 | N/A |
| 3/31/2019 | 0 | -19 | -14 | -14 | N/A |
| 12/31/2018 | 0 | -19 | -13 | -13 | N/A |
| 9/30/2018 | 0 | -18 | -13 | -13 | N/A |
| 6/30/2018 | 1 | -18 | N/A | -16 | N/A |
| 3/31/2018 | 1 | -20 | N/A | -17 | N/A |
| 12/31/2017 | 1 | -25 | N/A | -23 | N/A |
| 9/30/2017 | 0 | -31 | N/A | -29 | N/A |
| 6/30/2017 | 0 | -37 | N/A | -29 | N/A |
| 3/31/2017 | 0 | -39 | N/A | -33 | N/A |
| 12/31/2016 | 0 | -39 | N/A | -31 | N/A |
| 9/30/2016 | 0 | -38 | N/A | -29 | N/A |
| 6/30/2016 | 0 | -31 | N/A | -27 | N/A |
| 3/31/2016 | 0 | -31 | N/A | -24 | N/A |
| 12/31/2015 | 0 | -27 | N/A | -22 | N/A |
| 9/30/2015 | 0 | -25 | N/A | -19 | N/A |
| 6/30/2015 | 0 | -27 | N/A | -17 | N/A |
| 3/31/2015 | 0 | -18 | N/A | -15 | N/A |
| 12/31/2014 | 0 | -14 | N/A | -13 | N/A |
| 9/30/2014 | 0 | -11 | N/A | -11 | N/A |
| 6/30/2014 | 0 | -10 | N/A | -9 | N/A |
| 3/31/2014 | 0 | -14 | N/A | -8 | N/A |
| 12/31/2013 | 0 | -12 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XE7C is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XE7C is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XE7C is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XE7C's revenue is expected to decline over the next 3 years (-34.8% per year).
High Growth Revenue: XE7C's revenue is forecast to decline over the next 3 years (-34.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XE7C's Return on Equity is forecast to be high in 3 years time